呼吸器外科
東邦大学医療センター佐倉病院外科
東邦大学医療センター佐倉病院

【お問い合わせ先】

東邦大学医療センター
佐倉病院 呼吸器外科

〒285-8741
千葉県佐倉市下志津564-1
TEL:043-462-8811(代表)

学術活動

 

研究業績

英語論文

  1. Nagashima M, Kasai H, Yokota J, Nagamachi Y, Ichinose T, Sagai M. Formation of an oxidative DNA damage, 8-hydroxydeoxyguanosine, in mouse lung DNA after intratracheal instillation of diesel exhaust particles and effects of high dietary fat and beta-carotene on this process. Carcinogenesis 16: 1441-1445, 1995
  2. Nagashima M, Sasaki A, Morishita K, Takenoshita S, Nagamachi Y, Kasai H, Yokota J. Presence of human cellular protein(s) that specifically binds and cleaves 8-hydroxyguanine containing DNA. Mutation Research 383: 49-59, 1997
  3. Ichinose T, Yajima Y, Nagashima M, Takenoshita S, Nagamachi Y, Sagai M. Lung carcinogenesis and formation of 8-hydroxy-deoxyguanosine in mice by diesel exhaust particles. Carcinogenesis 18: 185-192, 1997
  4. Vincent F, Nagashima M, Takenoshita S, Khan MA, Gemma A, Hagiwara K, Bennett WP. Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta. Oncogene 15: 117-122, 1997
  5. Takenoshita S, Hagiwara K, Gemma A, Nagashima M, Ryberg D, Lindstedt BA, Bennett WP, Haugen A, Harris CC. Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles. Carcinogenesis 18: 1427-1429, 1997
  6. Zhou X, Wang XW, Xu L, Hagiwara K, Nagashima M, Wolkowicz R, Zurer I, Rotter V, Harris CC. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Research 59: 843-848, 1999
  7. Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K, Harris CC. Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18: 3415-3421, 1999
  8. Yang Q, Manicone A, Coursen JD, Linke SP, Nagashima M, Forgues M, Wang XW. Identification of a functional domain in a GADD45-mediated G2/M checkpoint. Journal of Biological Chemistry 275: 36892-36898, 2000
  9. Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J Riabowol K, Harris CC. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proceedings of the National Academy of Sciences of the United States of America 98: 9671-9676, 2001
  10. Nagashima M, Shiseki M, Pedeux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, Harris CC. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle, and apoptosis. Oncogene 22: 343-350, 2003
  11. Araki Y, Okamura S, Hussain, SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the wnt and ras pathways. Cancer Research 63: 728-734, 2003
  12. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Research 63: 2373-2378, 2003
  13. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, Ichimiya M, Sengupta S, Mechanic L, Okamura S, Hofseth LJ, Moake M, Nagashima M, Forrester KS, Harris CC. p53-Induced Up-Regulation of MnSOD and GPx but not Catalase Increases Oxidative Stress and Apoptosis. Cancer Research 64: 2350-2356, 2004
  14. Pedeux R, Sengupta S, Shen JC, Demidov ON, Saito S, Onogi H, Kumamoto K, Wincovitch S, Garfield SH, McMenamin M, Nagashima M, Grossman SR, Appella E, Harris CC. ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Molecular and Cellular Biology 25: 6639-6648, 2005
  15. Okano T, Gemma A, Hosoya Y, Hosomi Y, Nara M, Kokubo Y, Yoshimura A, Shibuya M, Nagashima M, Harris CC, Kudoh S. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncology Reports 15: 545-549, 2006
  16. Du Q, Park KS, Guo Z, He P, Nagashima M, Shao L, Sahai R, Geller DA, Hussain SP. Regulation of human nitric oxide synthase 2 expression by Wnt -catenin signaling. Cancer Research 66: 7024-7031, 2006
  17. Nagashima M, Katoh R, Sato Y, Tagami M, Kasai S, Ikeda K. Is there genetic polymorphism evidence for individual human sensitivity to opiates? Current Pain and Headache Reports 11: 115-123, 2007
  18. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC. Nutlin-3a activates p53 to both down-regulate Inhibitor of Growth 2 and up-regulate mir-34a, mir-34b and mir-34c expression, and induce senescence. Cancer Research 68: 3193-3203, 2008
  19. Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K, Nagai Y, Moriyama G, Miyazawa H, Ikebuchi K, Morita S, Kobayashi K, Hagiwara K. Frequency of and variables associated with the EGFR mutation and its subtypes. International Journal of Cancer, 126: 651-655, 2010
  20. Nishizawa D, Hayashida M, N-agashima M, Koga H, Ikeda K. Genetic polymorphisms and human sensitivity to opioid analgesics. Methods in Molecular Biology (Clifton, NJ, USA) 617: 395-420, 2010
  21. Saito M, Kumamoto K, Robles AI, Horikawa I, Furusato B, Okamura S, Goto A, Yamashita T, Nagashima M, Lee TL, Baxendale VJ, Rennert OM, Takenoshita S, Yokota J, Sesterhenn IA, Trivers GE, Hussain SP, Harris CC. Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS ONE, 5(11):15541, 2010
  22. Yoshida Y, Matsuzawa Y, Rikitake H, Wakabayashi T, Okada N, Kuroda T, Kawashima K, Tanabe M, Hiruta N, Nagashima M, Kawashima T. Mediastinal lymphadenopathy without cervical lymphadenopathy in a case of Kikuchi-Fujimoto disease. Internal Medicine, 50(6): 649-652, 2011
  23. Moriyama A, Nishizawa D, Kasai S, Hasegawa J, Fukuda KI, Nagashima M, Katoh R, Ikeda K. Association Between Genetic Polymorphisms of the β(1)-Adrenergic Receptor and Sensitivity to Pain and Fentanyl in Patients Undergoing Painful Cosmetic Surgery. Journal of pharmaceutical sciences, 121(1):48-57, 2013
  24. Nishizawa D, Fukuda K, Kasai S, Hasegawa J, Aoki Y, Nishi A, Saita N, Koukita Y, Nagashima M, Katoh R, Satoh Y, Tagami M, Higuchi S, Ujike H, Ozaki N, Inada T, Iwata N, Sora I, Iyo M, Kondo N, Won MJ, Naruse N, Uehara-Aoyama K, Itokawa M, Koga M, Arinami T, Kaneko Y, Hayashida M, Ikeda K. Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Molecular psychiatry, 19(1):55-62, 2014
  25. Nagashima M, Ooshiro M, Moriyama A, Sugishita Y, Kadoya K, Sato A, Kitahara T, Takagi R, Urita T, Yoshida Y, Tanaka H, Oshiro T, Okazumi S, Katoh R. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. Supportive Care in Cancer, 22(6):1579-1584, 2014

日本語論文

  1. 萩原弘一、長島誠: p53遺伝子ファミリー 最新医学 54: 2723-2727, 1999
  2. 長島誠: p53結合タンパク質INGファミリー 実験医学 18: 2225-2229, 2000
  3. 長島誠: p53コアクチベーターINGファミリー 実験医学 19: 1114-1120, 2001
  4. 長島誠: CADは早期肺癌補助診断に有用か? DIGITAL MEDICINE 4: 34-35 2004
  5. 長島誠、加藤良二 臨床検体を用いた癌悪性度診断-オーダーメイド医療の実現に向けて 東邦医学会雑誌 53: 221-226, 2006
  6. 長島誠 疼痛治療とオピオイド受容体多様性 治療学 43(3): 303-306, 2009
  7. 西澤大輔、長島誠、佐藤泰雄、田上惠、池田和隆 遺伝子多型と疼痛感受性、オピオイド感受性—基礎および臨床のデータから— 麻酔 58: 1093-1101, 2009
  8. 長島誠 テーラーメイド緩和医療実践のための工夫 癌の臨床 55(9): 671-677, 2009
  9. 森山彩子、西澤大輔、池田和隆 痛みや鎮痛における個人差の遺伝的要因 日本緩和医療薬学雑誌 2(4): 99-110, 2009
  10. 長島誠 外科医だからできる緩和医療 外科治療 102(6): 896-902, 2010
  11. 緩和ケア・がん性疼痛治療の進歩(分担執筆) がん治療最前線—米国癌学会(ASCO)のトピックスを中心に— がん治療レクチャー Vol 1 No 1 229-234, 2010
  12. 長島誠 個別化医療-癌緩和医療を中心に 外科 73(10): 1033-1038, 2011
  13. 大城充、長島誠 第2章 がん分子標的治療薬における副作用の疫学データと発現機序、診断・治療の現状 第3節 消化管穿孔 副作用軽減化 新薬開発 (株)技術情報協会 2012年9月発刊

受賞

  1. Federal Technology Transfer Award from the National Institutes of Health, August 24, 1999
  2. Traveler’s Grant 第99回日本外科学会総会 平成11年3月24-26日 福岡
  3. Traveler’s Grant 第100回日本外科学会定期学術集会 平成12年4月12-14日 東京
  4. 第46回日本癌治療学会総会 優秀演題 鎮痛関連遺伝子多型とオピオイド感受性個人差の相関 平成20年10月30日-11月1日 名古屋
  5. 第19回JPS優秀論文賞 Moriyama A, Nishizawa D, Kasai S, Hasegawa J, Fukuda KI, Nagashima M, Katoh R, Ikeda K. Association Between Genetic Polymorphisms of the β(1)-Adrenergic Receptor and Sensitivity to Pain and Fentanyl in Patients Undergoing Painful Cosmetic Surgery. Journal of pharmaceutical sciences, 121(1):48-57, 2013

特許

  1. International application published under the patent cooperation treaty (PCT). International publication number: WO 01/059114 A3. Title: Tumor suppressor gene, p47ING3. Inventors/Applicants: Harris Curtis C., Nagashima Makoto. International publication date: 16 August 2001.
  2. International application published under the patent cooperation treaty (PCT). International publication number: WO 2003/062398 A3. Title: New tumor suppressor gene, p28ING5. Inventors/Applicants: Harris Curtis C., Nagashima Makoto, Shiseki Masayuki, Pedeux Remy. International publication date: 31 July 2003.
  3. United States Patent 6,790,948. Title: Tumor suppressor gene p33ING2. Inventors: Harris Curtis C., Nagashima Makoto. September 14, 2004. (米国特許取得)
  4. 特開2008-557 (P2008-557A) 医療用点滴筒照明装置 長島誠、由岐友弘、渡辺進 平成20年1月10日公開
  5. United States Patent 7,335,749. Title: Tumor suppressor gene, p47Ing3. Inventors: Harris Curtis C., Nagashima Makoto. February 26, 2008.
  6. United States Patent 7,431,926. Title: Tumor suppressor gene p33ING2. Inventors: Harris Curtis C., Nagashima Makoto. October 7, 2008.
  7. United States Patent 7,432,349. Title: Tumor suppressor gene, p28ING5. Inventors: Harris Curtis C., Pedeux Remy, Nagashima Makoto, Shiseki Masayuki. October 7, 2008.